(Q39236297)

13 June 2018

title

Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial (English)

1 reference

13 June 2018

Maggie Chon U Cheang

12

0 references

Charles M. Perou

object named as

Charles M Perou

10

0 references

Edith A. Perez

1

object named as

Edith A Perez

1 reference

13 June 2018

Jennifer M Kachergus

5

object named as

Jennifer M Kachergus

1 reference

13 June 2018

author name string

Karla V Ballman

2

1 reference

13 June 2018

Afshin Mashadi-Hossein

3

1 reference

13 June 2018

Kathleen S Tenner

4

1 reference

13 June 2018

Nadine Norton

6

1 reference

13 June 2018

Brian M Necela

7

1 reference

13 June 2018

Jennifer M Carr

8

1 reference

13 June 2018

Sean Ferree

9

1 reference

13 June 2018

Frederick Baehner

11

1 reference

13 June 2018

E Aubrey Thompson

13

1 reference

13 June 2018

language of work or name

English

0 references

publication date

28 October 2016

1 reference

13 June 2018

Journal of the National Cancer Institute

published in

1 reference

13 June 2018

volume

109

1 reference

13 June 2018

issue

2

1 reference

13 June 2018

The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5903647

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5903647

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5903647

Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5903647

Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5903647

Comprehensive molecular portraits of human breast tumours

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5903647

A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5903647

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5903647

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5903647

Supervised risk predictor of breast cancer based on intrinsic subtypes

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5903647

Molecular portraits of human breast tumours

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5903647

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

17 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FJNCI%2FDJW207

Clinical implementation of the intrinsic subtypes of breast cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27794124

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/JNCI/DJW207

1 reference

13 June 2018

PMCID

5903647

1 reference

13 June 2018

PubMed ID

27794124

1 reference

13 June 2018